This is the text extract for Proposal relating to tiotropium bromide. Closed, browse documents here.

22 October 2009

Proposal relating to tiotropium bromide

PHARMAC is seeking feedback on a proposal relating to the listing of tiotropium bromide (Spiriva) inhalers in the Pharmaceutical Schedule. Spiriva (tiotropium bromide powder for inhalation, 18 μg per dose) is currently listed in the Pharmaceutical Schedule fully subsidised subject to Special Authority criteria for the treatment of moderate to severe chronic obstructive pulmonary disease (COPD). This proposal would result in a reduction in the net effective price of Spiriva through a rebate arrangement and extension of the subsidy and delisting protection for Spiriva until 1 July 2013, through a provisional agreement with Boehringer Ingelheim. This proposal would not involve any changes to the Special Authority criteria or otherwise affect subsidised access to tiotropium bromide.

Feedback sought PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Thursday, 12 November 2009 to: Sean Dougherty Therapeutic Group Manager PHARMAC Email: sean.dougherty@pharmac.govt.nz Fax: 04 460 4995 Post: PO Box 10 254, Wellington 6143

All feedback received before the closing date will be considered by PHARMAC’s Board (or Chief Executive acting under delegated authority) prior to making a decision on this proposal.

A314870 Page 1 of 1